• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评论：Jilkova, Z.M.等人，“肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”，2019年，第1554页。

Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.

作者信息

Dunnigan Anna

机构信息

Institute of Clinical Trials and Methodology, University College London, London WC1V 6LJ, UK.

出版信息

Cancers (Basel). 2020 Sep 18;12(9):2670. doi: 10.3390/cancers12092670.

DOI:10.3390/cancers12092670
PMID:32962028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7564357/
Abstract

I read with interest the article 'Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges' [...].

摘要

我饶有兴趣地阅读了《肝细胞癌领域中对PD-1/PD-L1免疫检查点抑制反应的预测因素：现状与挑战》这篇文章[……]。

相似文献

1
Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.评论：Jilkova, Z.M.等人，“肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”，2019年，第1554页。
Cancers (Basel). 2020 Sep 18;12(9):2670. doi: 10.3390/cancers12092670.
2
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.对“Jilkova, Z.M.等人。肝细胞癌领域中PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”评论的回复 2019年，，1554
Cancers (Basel). 2020 Sep 18;12(9):2673. doi: 10.3390/cancers12092673.
3
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战
Cancers (Basel). 2019 Oct 14;11(10):1554. doi: 10.3390/cancers11101554.
4
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合治疗的益处及肿瘤突变负担在肝细胞癌中的预测作用：系统评价和荟萃分析。
Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub 2022 Sep 18.
5
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.PD-1/PD-L1 通路及其免疫检查点抑制剂在人类癌症中的应用。
Front Immunol. 2022 Sep 13;13:964442. doi: 10.3389/fimmu.2022.964442. eCollection 2022.
6
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.调节性 T 细胞和检查点抑制在肝细胞癌中的作用。
Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066. doi: 10.1007/s00262-019-02427-4. Epub 2019 Nov 13.
7
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.CMTM4 抑制通过 PD-L1 增强胆管癌和肝细胞癌对 T 细胞介导的抗肿瘤免疫。
Hepatol Commun. 2022 Jan;6(1):178-193. doi: 10.1002/hep4.1682. Epub 2021 Jul 21.
8
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
9
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
10
The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.PD-1/PD-L1 抑制剂治疗晚期肝细胞癌患者中 PD-L1 表达的预测价值：系统评价和荟萃分析。
Cancer Med. 2023 Apr;12(8):9282-9292. doi: 10.1002/cam4.5676. Epub 2023 Mar 25.

引用本文的文献

1
Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer.氧化苦参碱通过下调IFN-γ抑制PD-L1，促进肝癌细胞铁死亡并增强抗PD-L1疗效。
J Hepatocell Carcinoma. 2024 Dec 6;11:2427-2440. doi: 10.2147/JHC.S492582. eCollection 2024.

本文引用的文献

1
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.对“Jilkova, Z.M.等人。肝细胞癌领域中PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”评论的回复 2019年，，1554
Cancers (Basel). 2020 Sep 18;12(9):2673. doi: 10.3390/cancers12092673.
2
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.肿瘤突变负荷作为预测多种癌症免疫治疗反应的独立标志物。
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.
3
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.